18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia

Abstract

Myeloid sarcoma in acute myeloid leukemia has been clearly defined by the World Health Organization but studies regarding the prevalence and the prognostic impact of extramedullary acute myeloid leukemia have not been conducted. We performed ¹⁸Fluoro-deoxy-Glucose Positron Emission Tomography/Computed Tomography scans in 10 patients with de novo and relapsed acute myeloid leukemia and histologically proven extramedullary disease. The scans were able to detect the known extramedullary lesions in 9 out of 10 patients (90%). Furthermore, additional extramedullary sites were detected in 6 patients (60%). Thus, it is possible to identify known and clinically undetectable extramedullary manifestations of acute myeloid leukemia. Since most of these patients relapsed within a short period of time after initiation of therapy or had refractory disease, the detection of extramedullary disease with ¹⁸Fluoro-deoxy-Glucose Positron Emission Tomography/Computed Tomography might be helpful in the development of individual treatment algorithms for these high-risk patients. (ClinicalTrials.gov Identifier: NCT01278069).

Introduction

Acute myeloid leukemia (AML) may present with extramedullary AML (EM-AML) at initial diagnosis or relapse. Myeloid sarcoma (MS) is defined as an extramedullary mass composed of myeloid blasts occurring at an anatomical site other than the bone marrow. Infiltrations occurring at any site in the body of leukemic patients are not classified as MS unless the mass destroys the tissue architecture.1 EM-AML is most frequently located in the skin but it can affect almost every part of the body.2–3 It occurs less commonly in patients with a transforming myelodysplastic syndrome (MDS) or myeloproliferative disorder (MPD).1 For AML patients who had undergone allogeneic hematopoietic stem cell transplantation (HSCT), retrospective data indicate relapse rates of 0.65% for extramedullary disease alone, compared to 30% in those with combined bone marrow and extramedullary disease.2,4–5 In the past, prognosis of MS or EM-AML has been a controversial topic. While an underlying MDS or MPD is thought to have a negative prognostic impact, de novo MS seems to be responsive to radiotherapy and/or chemotherapy.1,3 Recent data indicate that patients with EM-AML treated with autologous or allogeneic HSCT have a better overall survival (OS) compared to patients treated with chemotherapy alone.6 In a prospective trial addressing long-term survival in chemotherapy-refractory patients with AML who had undergone allogeneic HSCT, those with EM-AML had an inferior outcome after HSCT compared with those without EM-AML.7 In a large meta-analysis of eight prospective AML treatment trials, EM-AML was identified as an independent prognostic factor contributing to shorter overall survival in patients with chromosome 8 trisomy.8 There are no data on the prevalence of MS or EM-AML at initial diagnosis and the existing information about this condition is mostly based on retrospective and clinical analyses. Fluoro-deoxy-Glucose Positron Emission Tomography (F-FDG-PET)/Computed Tomography (CT) is able to detect metabolically active tissue and has been shown to be effective in the detection and localization of various hematologic malignancies, particularly in Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). It has been shown to be of prognostic importance and is, therefore, incorporated in the response criteria.9 Recent case reports have shown that F-FDG-PET/CT might be a useful tool in detecting extramedullary AML.10–13 In two retrospective studies of 5 and 6 patients with EM-AML, F-FDG-PET was more or at least equally effective in the detection of extramedullary disease.14 Furthermore, F-FDG-PET/CT was more accurate in detecting lesions than F-FDG-PET or CT alone.15 The aim of this study was to investigate the feasibility of using F-FDG-PET/CT scans to detect EM-AML in patients with newly diagnosed AML, as well as relapsed AML with histologically proven extramedullary disease.

Design and Methods

Patients

A total of 10 patients with AML and histologically proven extramedullary disease underwent total body F-FDG-PET/CT imaging at diagnosis to detect further manifestations. All patients had previously given their written informed consent for the procedure. Approval to review the medical records was obtained from the Ethics Committee of the Medical Faculty Carl Gustav Carus, Dresden (EK95032011). Blood, bone marrow, and MS (if available) tissue samples were obtained at diagnosis. Polymerase chain reaction (PCR) amplification of NPM1 exon 12 and FLT3-ITD mutation analyses were performed as previously described.16 Cytogenetic analyses were performed using standard techniques for chromosome banding and fluorescence in situ hybridization. MDS-derived AML (mdsAML) was defined by at least one documented bone marrow examination revealing MDS at least three months prior to the diagnosis of AML. Therapy-related AML (tAML) was defined as AML developing after cytotoxic chemotherapy and/or radiation therapy administered for a prior neoplastic or non-neoplastic disorder.

Imaging

Hybrid PET/CT scans were performed using a Biograph 16 W (Siemens Medical Solutions Inc., Knoxville, TN, USA) containing a 16-slice CT scanner. Unenhanced CT scans for attenuation correction were performed in a cranio-caudal direction from the skull base to lower thighs. Scanning parameters were as follows: 10 mAs, 120 kV, online tube current modulation, 1.5 mm slice collimation, 0.5–0.75 s rotation time, and reconstruction of 5 mm slices. The diagnostic CT scans of skull base, neck, thorax, abdomen and small pelvis were performed as primary contrast enhanced continuous scans. The scanning parameters were 1.5 mm slice collimation, 100 kV tube voltage, 180 mAs amperage with online current modulation using Siemens CareDose 4D and a rotation time of 0.75 sec. As intravenous contrast media, we used 120 ml Ultravist 370 (Bayer Schering Pharma, Leverkusen, Germany) followed by 50 ml of 0.9% NaCl solution to wash out remaining contrast media of the injection system. The injection was given automatically via a Medtron Accutron CT-D mobile system (Medtron AG, Saarbrücken, Germany) with a flow rate of 3 mL per sec. The CT scans were started automatically after a delay of 55 sec to the start of contrast media injection. Primary axial reconstructions in 3 mm slice thickness in soft tissue, lung and a bone window were calculated at post processing of the raw data.

All patients had a mean estimated glomerular filtration rate (eGFR) (according to the Modification of Diet in Renal Disease study equation)17 of 88 ml*min*1,73 m prior to F-FDG-PET/CT (range 44–107) and a mean eGFR after F-FDG-PET/CT of 87 ml*min*1,73 m (range 45–115) with no patient showing a continuous deterioration in eGFR thereafter (data not shown).

PET 3-dimensional (3D) emission scans with a median activity of 346 MBq (range 225–391 MBq) of FDG (GlucoRos Helmholtz Center, Dresden-Rossendorf, Germany) were taken 60 min (±10 min) post injection.18 For each scan, the blood glucose level was measured immediately prior to FDG injection. Intraindividual variation was low (<20%) and the protocol was arranged to minimize differences in tumor uptake, resulting in intraindividual PET studies which could not be compared over time. The patients did not receive any sedative and/or diuretic medication in the FDG accumulation phase and they were instructed not to talk in order to avoid muscular FDG uptake, which could have hampered interpretation of the PET images.

The acquisition time per bed position, for the emission scan only, was 3 min. Uncorrected emission images and CT-based attenuation-corrected images were reconstructed using four iterations, eight subsets, and a 5 mm 3D Gaussian filter.

Results and Discussion

Patients’ characteristics at the time of F-FDG-PET/CT imaging are shown in Table 1. Notably, 5 of the 10 patients presented with EM-AML at relapse seven months to nine years after allogeneic HSCT. Cytogenetic analyses of bone marrow aspirates were available for 8 patients at initial diagnosis. Interestingly, 3 of the 5 patients who presented with EM-AML after allogeneic HSCT had a del(5q) karyotype. Three patients presented with chromosome 8 trisomy. Five patients had a complex karyotype. Only one of 6 patients had a mutated NPM1 gene at the time of diagnosis. None of the patients in whom the FLT3-mutational status was tested harbored a mutated FLT3 gene. Interestingly, only 4 patients complained of pain as a symptom of the EM mass while the remaining 6 patients had painless EM tumors.

F-FDG-PET/CT imaging time points, procedures, and findings are shown in Table 2. F-FDG-PET/CT imaging was performed in these 10 patients because they had his-tologically proven EM-AML; imaging was performed a median of 12 days (range 1–38 days) after histological diagnosis and prior to the initiation of systemic therapy. In 6 of the 10 AML patients (60%), F-FDG-PET/CT identified new EM manifestations that were not clinically detectable. This is in agreement with previous reports in smaller patient cohorts.14–15 In one patient (UPN 6), the histologically proven EM could not be detected by F-FDG-PET/CT. It is important to note that the SUV_max (standard uptake value given as the maximum pixel value in the tumor) ranged from 2.1 to 9.3 and showed intra- and interindividual variation; it was generally lower than that previously reported in patients with HL or NHL.13–15,19 Follow-up F-FDG-PET/CT was performed in 3 patients. Patient UPN 1 had follow-up imaging on day 25 after salvage chemotherapy and showed a decrease in breast tumor size (5.0 x 2.4 vs. 5.5 x 3.3 cm) and SUV_max (3.4 vs. 5.6) even though F-FDG-PET/CT was performed very soon after the initiation of treatment (Figure 1). Patient UPN 2, who had isolated MS, decided not to undergo any therapy but returned to the hospital 57 days later due to abdominal complaints. This patient then had follow-up F-FDG-PET/CT showing an increase in size of the presacral tumor (5.8×4.7 x 5.9 cm vs. 2.9 x 3.2 x 3.0 cm) and SUV_max (6.1 vs. 3.7). Patient UPN 3 received local irradiation of the glenoid cavity and acetabulum and systemic therapy with lenalidomide due to a del(5q) karyotype. This patient had a mixed response with no change in the dimensions of the osteolytic tumors and an increase in SUV_max in the glenoid (5.3 vs. 2.3) and the acetabulum (5.7 vs. 4.6) 27 days after first imaging and initiation of treatment.

To the best of our knowledge, this is the largest study examining the suitability of F-FDG-PET/CT imaging for the detection of extramedullary disease in patients with AML. One study on the utility of 3′-deoxy-3′-F-fluorothymidine (F-FLT)-PET in a series of patients with AML, in which patients underwent either F-FLT-PET or -PET/CT before confirmation of EM-AML, has been reported.

Table 1.Patients’ characteristics at the time of ¹⁸FDG-PET/CT.

Interestingly, 4 of the 10 patients were diagnosed as harboring EM-AML, suggesting a significant percentage of AML with occult extramedullary manifestations.20 This finding could be clinically relevant since EM-AML may respond differently to standard chemotherapy. By applying F-FDG-PET/CT in our study, we were able to detect EM-AML in patients with de novo AML, as well as AML relapsed after chemotherapy and allogeneic HSCT. EM appeared to occur more frequently in patients after allogeneic HSCT, supporting clinical observations and studies investigating the prevalence of extramedullary relapse in patients with AML after allogeneic HSCT.2,5 Cytogenetic studies of AML bone marrow aspirates in our patients showed a high proportion of del(5q) aberrations, which has not been observed at this frequency in EM-AML in the literature. However, the number of patients included in our study was too small to allow us to draw any definitive conclusions from this observation. Moreover, our result could reflect a bias since aggressive AML is associated with more frequent relapse and, therefore, occurs more often with extramedullary disease. Trisomy of chromosome 8 was also frequently observed in our patients as shown in previous reports.6,8 A high prevalence of NPM1 mutations has been reported in EM-AML.21–22 We could not confirm this observation nor the suggested inv(16) and t(8;21) alterations which might be associated with EM-AML1 due to the limitations imposed by the total number of only 10 patients. Lack of molecular information presented a further limitation. In most patients with EM-AML, F-FDG-PET/CT was able to detect additional extramedullary sites, whereas one patient with EM-AML had a false negative F-FDG-PET/CT result (UPN 6). We are aware that due to F-FDG distribution and metabolism, detection of EM in the heart, the central nervous system and urinary tract is difficult. However, these manifestations might be detected by routinely performed lumbar puncture in cases of neurological or psychiatric abnormalities and by echocardiography. Since the median SUV_max was lower than that observed in other hematologic diseases, a combination with CT seems reasonable in terms of anatomical land marking and collecting morphological aspects to determine the most exact diagnosis. Whether the lower SUV_max reflects lower growth kinetics in EM-AML as compared to other hematologic malignancies remains speculative. Therefore, F-FDG-PET may be less sensitive in the detection of extramedullary lesions with low FDG uptake, especially when located in areas with physiologically high background FDG uptake as previously suggested.14–15 In these cases, magnetic resonance imaging with diffusion weighted imaging (MRI-DWI) could be used as a complementary diagnostic tool, although this remains challenging since imaging findings lack specificity.15

Table 2.¹⁸FDG-PET/CT imaging characteristics.

Figure 1.(A) ¹⁸F-FDG-PET scan of patient UPN 1 at diagnosis of extramedullary AML. (B) Coronal and transversal ¹⁸F-FDG-PET/CT fusion images of the EM in the left mammary gland at diagnosis. (C) ¹⁸F-FDG-PET scan of the same patient after salvage chemotherapy (note: higher bone marrow ¹⁸F-FDG uptake due to higher bone marrow activity). (D) Coronal and transversal ¹⁸F-FDG-PET/CT fusion images of the EM in the left mammary gland after salvage chemotherapy (note: higher bone marrow ¹⁸F-FDG uptake due to higher bone marrow activity).

It is generally accepted that local treatment of EM-AML is not sufficient for curative therapy and that allogeneic HSCT is superior compared to other therapies in this context.6,23 It remains a subject of debate whether quiescent AML cells serving as a reservoir for occult leukemia prefer infiltration and fusion with vascular endothelium, which has recently been observed, or whether they preferentially move toward and persist in bradytrophic sites (“sanctuary sites”).24 EM in AML is clinically difficult to diagnose, appears to have an inferior outcome without allogeneic HSCT, and its prevalence at diagnosis has still not been evaluated. These factors indicate the need for an increased level of alertness for this entity in patients with AML. Therefore, F-FDG-PET/CT should be applied in patients with EM-AML at diagnosis, before treatment initiation and thereafter as early assessment, and in complete remission (CR) in order to evaluate treatment response.

In conclusion, this single center study describes the detection of extramedullary disease by F-FDG-PET/CT in patients with histologically proven EM-AML. The ability to detect EM-AML, with its poor clinical trajectory, using a non-invasive diagnostic procedure would be a welcome adjunct to the management of this AML subtype. An observational trial with F-FDG-PET/CT for newly diagnosed and relapsed AML patients is currently underway to estimate the prevalence of EM in AML (ClinicalTrials.gov Identifier: NCT01278069).

Footnotes

• KZ and MS contributed equally to this article.
• Funding: this study was presented in part at the 52^nd Annual Meeting of the American Society of Hematology, December 4–7, 2010, Orlando, Florida, USA.
• Authorship and Disclosures The information provided by the authors about contributions from persons listed as authors and in acknowledgments is available with the full text of this paper at www.haematologica.org.
• Financial and other disclosures provided by the authors using the ICMJE (www.icmje.org) Uniform Format for Disclosure of Competing Interests are also available at www.haematologica.org.

• Received March 29, 2011.
• Revision received May 24, 2011.
• Accepted June 10, 2011.